HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $9
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Kronos Bio (NASDAQ:KRON) but has lowered the price target from $10 to $9.

August 21, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kronos Bio's price target has been lowered from $10 to $9 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintenance of the 'Buy' rating indicates that the analyst still sees potential in the stock, which could counterbalance the negative sentiment to some extent.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100